Similarly, pre-treatment with an inhibitor of RhoA (C3) and Y-27632 led to the decrease in leptin-induced expression of urokinase plasminogen activator and inhibited the invasiveness of ovarian cancer (OVCAR3, SKOV-3, CAOV-3) cells [172]. This evidence concerns the gene RHOA and ovarian carcinoma.